NCT07010159Phase 2, phase 3Recruiting

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

Study sponsor: Kiniksa Pharmaceuticals International, plc · KNSA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-12-31Estimated

Enrollment · participants325Estimated

Source updated2026-08-26Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-11 · 1 field changed

Planned enrollment increased by 160 participants

− Before

~~165 participants (planned)~~

+ After

325 participants (planned)

Check registry source